Silence Therapeutics PLC
SLN5.030USD
+0.020+0.40%
終値 09/18, 16:00（ET）15分遅れの株価
712.76M時価総額
損失額直近12ヶ月PER
詳細情報 Silence Therapeutics PLC 企業名
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
企業情報
企業コードSLN
会社名Silence Therapeutics PLC
上場日Jan 05, 2010
最高経営責任者「CEO」Mr. Craig A. Tooman
従業員数116
証券種類Depository Receipt
決算期末Jan 05
本社所在地72 Hammersmith Road
都市LONDON
証券取引所NASDAQ Global Market Consolidated
国United Kingdom
郵便番号W14 8TH
電話番号442034576900
ウェブサイトhttps://www.silence-therapeutics.com/
企業コードSLN
上場日Jan 05, 2010
最高経営責任者「CEO」Mr. Craig A. Tooman
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
データなし
地域別USD
会社名
収益
比率
United Kingdom
43.11M
99.67%
Germany
144.00K
0.33%
USA
0.00
0.00%
事業別
地域別
データなし
株主
更新時刻: Sat, Aug 16
更新時刻: Sat, Aug 16
株主統計
種類
株主統計
株主統計
比率
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
6.16%
Redmile Group, LLC
4.58%
Lombard Odier Asset Management (USA) Corp.
3.92%
他の
54.54%
株主統計
株主統計
比率
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
6.16%
Redmile Group, LLC
4.58%
Lombard Odier Asset Management (USA) Corp.
3.92%
他の
54.54%
種類
株主統計
比率
Individual Investor
24.38%
Investment Advisor
18.67%
Investment Advisor/Hedge Fund
10.18%
Hedge Fund
4.99%
Venture Capital
3.35%
Research Firm
3.17%
Private Equity
2.05%
Bank and Trust
0.02%
他の
33.18%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
131
33.68M
71.31%
-14.18M
2025Q1
133
31.94M
67.63%
-14.00M
2024Q4
128
31.43M
66.56%
-10.23M
2024Q3
111
35.93M
77.05%
-5.19M
2024Q2
96
34.94M
74.95%
-4.57M
2024Q1
86
35.43M
76.18%
+4.14M
2023Q4
61
30.21M
78.15%
-609.51K
2023Q3
58
32.62M
88.08%
+1.55M
2023Q2
54
31.78M
89.08%
+2.79M
2023Q1
52
31.17M
88.54%
+2.74M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Griffiths (Richard Ian)
11.51M
24.38%
+543.58K
+4.95%
Jun 25, 2025
TCG Crossover Management, LLC
3.03M
6.42%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.79M
5.91%
-41.94K
-1.48%
Mar 31, 2025
Redmile Group, LLC
2.21M
4.69%
-184.37K
-7.68%
Mar 31, 2025
Lombard Odier Asset Management (USA) Corp.
1.85M
3.92%
-6.29K
-0.34%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.90M
4.01%
+333.48K
+21.34%
Mar 31, 2025
Vivo Capital, LLC
1.11M
2.34%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.04M
2.21%
-7.25K
-0.69%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.15M
2.43%
--
--
Mar 31, 2025
Nextech Invest, Ltd.
952.40K
2.02%
--
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
1.3%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.01%
SPDR S&P International Small Cap ETF
0.01%
ActivePassive International Equity ETF
0%
Tema Heart & Health ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
比率1.3%
ProShares Ultra Nasdaq Biotechnology
比率0.03%
Invesco Nasdaq Biotechnology ETF
比率0.03%
iShares Biotechnology ETF
比率0.01%
SPDR S&P International Small Cap ETF
比率0.01%
ActivePassive International Equity ETF
比率0%
Tema Heart & Health ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
